Holen Sie sich die Stockscreener-App
2.12
4.07%
-0.09
Handel nachbörslich:
2.12
Schlusskurs vom Vortag:
$2.21
Offen:
$2.2
24-Stunden-Volumen:
4.23M
Relative Volume:
1.07
Marktkapitalisierung:
$562.11M
Einnahmen:
$194.75M
Nettoeinkommen (Verlust:
$-51.26M
KGV:
-7.5714
EPS:
-0.28
Netto-Cashflow:
$-23.38M
1W Leistung:
-33.12%
1M Leistung:
-25.09%
6M Leistung:
-13.47%
1J Leistung:
+25.44%
1-Tages-Spanne:
$2.065
$2.22
1-Wochen-Bereich:
$2.065
$3.20
52-Wochen-Spanne:
$1.52
$4.0787
Akebia Therapeutics Inc Stock (AKBA) Company Profile
Firmenname
Akebia Therapeutics Inc
Sektor
Telefon
617-871-2098
Adresse
245 FIRST STREET, CAMBRIDGE, MA
Vergleichen Sie AKBA mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
AKBA
Akebia Therapeutics Inc
|
2.12 | 585.97M | 194.75M | -51.26M | -23.38M | -0.28 |
|
ZTS
Zoetis Inc
|
144.35 | 63.86B | 9.39B | 2.62B | 2.22B | 5.8121 |
|
TAK
Takeda Pharmaceutical Co Adr
|
13.42 | 42.46B | 29.96B | 957.25M | 4.77B | 0.2956 |
|
HLN
Haleon Plc Adr
|
9.38 | 41.28B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
20.52 | 23.49B | 16.70B | -157.13M | 1.19B | -0.1446 |
|
UTHR
United Therapeutics Corp
|
438.66 | 19.18B | 3.08B | 1.24B | 1.07B | 25.61 |
Akebia Therapeutics Inc Stock (AKBA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-06-04 | Fortgesetzt | H.C. Wainwright | Buy |
| 2025-04-28 | Eingeleitet | Leerink Partners | Outperform |
| 2025-04-01 | Eingeleitet | Jefferies | Buy |
| 2023-11-29 | Fortgesetzt | BTIG Research | Buy |
| 2023-08-28 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2023-05-31 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2022-03-31 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2022-03-31 | Herabstufung | Mizuho | Buy → Neutral |
| 2022-03-31 | Herabstufung | Needham | Buy → Hold |
| 2022-03-31 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2021-03-08 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2021-01-29 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2019-11-14 | Bestätigt | Needham | Buy |
| 2019-08-06 | Bestätigt | H.C. Wainwright | Buy |
| 2019-07-11 | Bestätigt | H.C. Wainwright | Buy |
| 2019-05-02 | Eingeleitet | JP Morgan | Overweight |
| 2019-03-20 | Eingeleitet | Citigroup | Neutral |
| 2018-09-07 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2018-08-10 | Bestätigt | Needham | Buy |
| 2018-06-06 | Bestätigt | H.C. Wainwright | Buy |
| 2017-12-19 | Eingeleitet | Piper Jaffray | Overweight |
| 2017-12-07 | Eingeleitet | BTIG Research | Buy |
| 2017-09-15 | Eingeleitet | RBC Capital Mkts | Sector Perform |
| 2017-07-10 | Bestätigt | H.C. Wainwright | Buy |
| 2017-04-27 | Bestätigt | H.C. Wainwright | Buy |
| 2017-04-27 | Bestätigt | Needham | Buy |
| 2016-12-27 | Bestätigt | H.C. Wainwright | Buy |
| 2016-12-20 | Bestätigt | JMP Securities | Mkt Outperform |
| 2016-11-15 | Eingeleitet | Aegis Capital | Buy |
| 2016-09-29 | Eingeleitet | Brean Capital | Buy |
| 2016-03-16 | Bestätigt | Needham | Buy |
| 2016-01-21 | Eingeleitet | Credit Suisse | Neutral |
Alle ansehen
Akebia Therapeutics Inc Aktie (AKBA) Neueste Nachrichten
Akebia Therapeutics reports inducement grants under Nasdaq listing rule 5635(c)(4) - MarketScreener
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Globe and Mail
Akebia (NASDAQ: AKBA) grants inducement options to new hires at $2.21 for 51,825 shares - Stock Titan
Akebia Therapeutics Securities Lawsuit Investigation - Claim Depot
Why Akebia Therapeutics Inc. (AX9) stock attracts wealthy investorsQuarterly Market Summary & Verified Momentum Stock Alerts - newser.com
Why institutional investors increase stakes in Akebia Therapeutics Inc. (AX9) stockDip Buying & Long-Term Capital Growth Strategies - newser.com
Live market analysis of Akebia Therapeutics Inc.Market Activity Recap & Safe Entry Trade Reports - newser.com
How high can Akebia Therapeutics Inc. stock goQuarterly Portfolio Summary & Target Return Focused Picks - newser.com
Will earnings trigger a reversal in Akebia Therapeutics Inc.July 2025 Patterns & Entry and Exit Point Strategies - newser.com
How Akebia Therapeutics Inc. stock reacts to job market dataPortfolio Performance Report & Daily Profit Focused Stock Screening - newser.com
Akebia Therapeutics Inc. stock retracement – recovery analysisEarnings Miss & Daily Volume Surge Trade Alerts - newser.com
What makes Akebia Therapeutics Inc. stock attractive to growth fundsGap Down & Free Long-Term Investment Growth Plans - newser.com
How rising interest rates impact Akebia Therapeutics Inc. stockJuly 2025 Price Swings & Verified Momentum Stock Alerts - newser.com
How strong dollar benefits Akebia Therapeutics Inc. (AX9) stockWeekly Stock Recap & Scalable Portfolio Growth Ideas - newser.com
Analyzing Akebia Therapeutics Inc. with risk reward ratio chartsQuarterly Earnings Report & Long-Term Capital Growth Strategies - newser.com
Wall Street Zen Upgrades Akebia Therapeutics (NASDAQ:AKBA) to "Strong-Buy" - MarketBeat
HC Wainwright Issues Pessimistic Forecast for AKBA Earnings - MarketBeat
Is Akebia Therapeutics Inc. (AX9) stock undervalued at current priceJuly 2025 Volume & Risk Managed Investment Signals - newser.com
Can Akebia Therapeutics Inc. stock sustain revenue growthJuly 2025 Macro Moves & Low Risk Entry Point Guides - newser.com
Is Akebia Therapeutics Inc. (AX9) stock attractive for growth fundsJuly 2025 Institutional & Safe Investment Capital Preservation Plans - newser.com
Akebia Therapeutics (NASDAQ:AKBA) Stock Price Up 7.4%Here's Why - MarketBeat
Akebia Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business Highlights - ADVFN
Akebia Therapeutics (NASDAQ:AKBA) Price Target Lowered to $6.00 at HC Wainwright - MarketBeat
Akebia plummets as it abandons Vafseo for non-dialysis patients - MSN
Analysts Offer Insights on Healthcare Companies: Atricure (ATRC), Tectonic Therapeutic (TECX) and Akebia Therapeutics (AKBA) - The Globe and Mail
Akebia Therapeutics (AKBA) Expected to Announce Earnings on Thursday - MarketBeat
Is this a good reentry point in Akebia Therapeutics Inc.2025 Support & Resistance & Fast Gaining Stock Reports - newser.com
Akebia Therapeutics (AKBA) Valuation in Focus After VALOR Trial Decision Alters Vafseo Strategy - Sahm
Will Akebia Therapeutics Inc. stock attract more institutional investorsWeekly Trade Recap & Weekly Hot Stock Watchlists - newser.com
Investigation Alert: Levi & Korsinsky Investigates Securities Fraud Claims Against Akebia Therapeutics, Inc. (AKBA) - ACCESS Newswire
Akebia Therapeutics Hits Day Low of $2.08 Amid Price Pressure - Markets Mojo
Is Akebia Therapeutics Inc. (AX9) stock attractive for dividend growthJuly 2025 News Drivers & Expert Verified Stock Movement Alerts - newser.com
Akebia Therapeutics (AKBA) Is Down 29.9% After Ending VALOR Trial for Non-Dialysis CKD Patients - Yahoo Finance
Akebia Therapeutics (NASDAQ:AKBA) Price Target Lowered to $5.00 at BTIG Research - MarketBeat
Akebia Therapeutics (NASDAQ:AKBA) Shares Gap DownHere's Why - MarketBeat
How Akebia Therapeutics Inc. stock trades during market volatilityInsider Buying & Stepwise Trade Signal Guides - newser.com
Akebia Therapeutics (AKBA) Receives Revised Price Target from HC Wainwright & Co. | AKBA Stock News - GuruFocus
Akebia Therapeutics to Report Third Quarter 2025 Financial Results and Discuss Recent Business Highlights - MarketScreener
HC Wainwright & Co. Maintains Akebia Therapeutics (AKBA) Buy Recommendation - Nasdaq
Strategic Shift and Market Opportunities Drive Buy Rating for Akebia Therapeutics - TipRanks
Akebia price target lowered to $6 from $8 at H.C. Wainwright - TipRanks
Finanzdaten der Akebia Therapeutics Inc-Aktie (AKBA)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.35%
0.90%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):